



Published in final edited form as:

Nat Struct Mol Biol. 2016 November ; 23(11): 958–964. doi:10.1038/nsmb.3308.

Regulation of CED-3 caspase localization and activation by *C. elegans* nuclear membrane protein NPP-14

Xudong Chen^{1,2,*}, Yue Wang^{1,*}, Yu-Zen Chen^{3,*}, Brian L. Harry³, Akihisa Nakagawa³, Eui-Seung Lee³, Hongyan Guo¹, and Ding Xue^{1,2,3,†}

¹School of Life Sciences, Tsinghua University, Beijing 100084, P.R. China

²Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Tsinghua University, Beijing 100084, P.R. China

³Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO 80309, USA

Abstract

Caspases are cysteine proteases with critical roles in apoptosis. The *Caenorhabditis elegans* caspase CED-3 is activated by autocatalytic cleavage, a process enhanced by CED-4. Here we report that CED-3 zymogen localizes to the perinuclear region in *C. elegans* germ cells and that CED-3 autocatalytic cleavage is held in check by *C. elegans* nuclei and activated by CED-4. The nuclear pore protein NPP-14 interacts with the prodomain of CED-3 zymogen, colocalizes with CED-3 *in vivo*, and inhibits CED-3 autoactivation *in vitro*. Several missense mutations in the CED-3 prodomain result in stronger association with NPP-14 and reduced CED-3 activation by CED-4 in the presence of nuclei or NPP-14, leading to cell death defects. Those same mutations enhance autocatalytic cleavage of CED-3 *in vitro* and increase apoptosis *in vivo* in the absence of *npp-14*. Our results reveal a critical role for nuclei and nuclear membrane proteins in regulating activation and localization of CED-3.

Apoptotic caspases are a family of conserved cysteine proteases that play central roles in activating and executing apoptosis in diverse organisms^{1,2}. They are initially synthesized as inactive zymogens, containing an N-terminal prodomain or caspase recruitment domain (CARD) and two catalytic subunits known as the large and the small subunits. In cells that receive cell death stimuli, caspase zymogens either undergo autoproteolytic activation through induced dimerization or oligomerization of the zymogens, or are proteolytically activated by upstream caspases or proteases^{1,2}. The activated caspases then act by cleaving a

[†]Correspondence and requests should be addressed to D.X. (ding.xue@colorado.edu).

*These authors contributed equally to this work

AUTHOR CONTRIBUTIONS

X.D.C., Y.W., Y.Z.C., and D.X. conceived the research and designed and analyzed experiments. X.D.C. carried out all CED-3 *in vitro* assays and some immunoblotting and protein binding assays. Y.W. performed the RNAi screen, microscopy imaging, some protein binding assays, and some of the somatic cell death assays. Y.Z.C. performed germ cell death and some of the somatic cell death assays, microscopy imaging, and some biochemical assays. B.H., A.N., E.S.L., and H.Y.G. assisted in some of experiments. X.D.C., Y.W., Y.Z.C., and D.X. wrote the paper.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

plethora of cellular proteins, leading to self-destruction of the cell, including nuclear membrane breakdown, chromosome fragmentation, apoptotic body formation, and clearance by phagocytes³. Given the critical roles of caspases in apoptosis, the activation and activity of caspases are tightly regulated at multiple levels and by both positive and negative regulators so that they are suppressed in cells that live, but swiftly activated in cells that need to undergo apoptosis^{1,2}.

The *C. elegans ced-3* gene is essential for apoptosis and encodes a caspase that is the founding member of the apoptotic caspases^{4,5}. The analysis of CED-3 activation and regulation during apoptosis has provided critical insights into the activation and functions of caspases and apoptosis in general. In *C. elegans* cells that live, the CED-4 protein, a homolog of the human apoptotic protease activating factor-1 (Apaf-1)^{6,7}, is complexed with the cell death inhibitor CED-9 in a 2:1 stoichiometric ratio and tethered to the surface of mitochondria through CED-9⁸⁻¹². During apoptosis, the cell-death initiator EGL-1 is transcriptionally upregulated, binds to CED-9, and triggers dissociation of the CED-4 dimer from CED-9¹¹⁻¹³. Released CED-4 dimers subsequently oligomerize and translocate to the perinuclear region to activate apoptosis^{11,12,14}. It is not understood why CED-4 relocates to nuclei during apoptosis.

Related to the dynamic movement of CED-4 during apoptosis, several key questions regarding CED-3 remain unanswered. In particular, the subcellular localization of CED-3 in *C. elegans*, which will shed light on how CED-3 is activated and how it acts to cause apoptosis, has been a major mystery. In addition, the role of the prodomain of the CED-3 zymogen in *C. elegans* apoptosis is an enigmatic issue, as the prodomain of CED-3 appears to be completely dispensable for CED-3 activation and activities *in vitro*^{15,16}, but is critical for the killing activity of CED-3 *in vivo*^{4,17}.

In this study, we set out to investigate where CED-3 localizes and how the prodomain of CED-3 affects apoptosis. We find that CED-3 also localizes to the perinuclear region in *C. elegans* germ cells, which provides a causal link for the translocation of CED-4 oligomers to nuclei during apoptosis. Moreover, we identify a nuclear pore protein NPP-14 that is critical not only for the perinuclear localization of CED-3 but also for inhibiting CED-3 zymogen autoactivation in living cells. Finally, we demonstrate that several unique CED-3 prodomain mutations enhance binding of the CED-3 zymogen with NPP-14, leading to inhibition of CED-4-induced CED-3 activation *in vitro* and apoptosis *in vivo*.

RESULTS

CED-3 prodomain mutations can enhance CED-3 autoactivation

Several loss-of-function (*If*) mutations in *ced-3* (*n718*, *n1040* and *n2439*) result in single amino acid substitutions (G65R, L27F and L30F, respectively) in the prodomain of the CED-3 caspase^{4,17}. These mutations cause strong reduction of apoptosis, as monitored by the number of persistent cell corpses in a *ced-1(e1735)* mutant background that is defective in cell corpse clearance (Table 1)¹⁸. For example, an average of 31 persistent cell corpses were observed in *ced-1(e1735)* embryos, whereas virtually no cell corpse was detected in *ced-1(e1735); ced-3(n718 G65R)* embryos (Table 1), indicating that *ced-3(n718 G65R)*

animals are defective in cell death. Similarly, reduced numbers of persistent cell corpses were seen in *ced-1(e1735); ced-3(n1040L27F)* and *ced-1(e1735); ced-3(n2439L30F)* embryos (13 and 7 cell corpses on average, respectively)(Table 1). We confirmed these observations by quantifying the number of cells that failed to undergo apoptosis in the anterior pharynx of these animals (16 cells are programmed to die in this region of wild-type animals)¹⁷. *ced-1(e1735); ced-3(n718 G65R)*, *ced-1(e1735); ced-3(n1040L27F)*, and *ced-1(e1735); ced-3(n2439L30F)* larvae have an average of 12.6, 10.3 and 12.0 extra undead cells, respectively, indicating strong cell death defects (Supplementary Table 1). Because the prodomain of CED-3 appears to be dispensable for CED-3 activity or activation *in vitro*^{15,16}, these results raise important questions regarding the role of the CED-3 prodomain in regulating CED-3 activation, activity, or apoptosis *in vivo*.

We first performed *in vitro* assays to examine if these prodomain mutations affect CED-3 zymogen autoproteolytic activation or CED-3 activation induced by oligomeric CED-4, the activated form of CED-4¹². In CED-3 autoactivation assays, ³⁵S-Methionine-labeled CED-3 zymogen synthesized in the rabbit reticulocyte lysate initially existed as an unprocessed precursor and was slowly autocleaved to generate some processed forms, including one that was visible at the 41 kD position by the 90-min time point (Fig. 1a, lanes 1–4, and Supplementary Fig. 1a,c)^{12,19}. In contrast, CED-3(L27F), CED-3(L30F) and CED-3(G65R) zymogens displayed much stronger autoproteolytic activation and were mostly autoprocessed by the 90-min time point (Fig. 1a, lanes 5–12, 17–20, and Supplementary Fig. 1a,c). This is surprising, because *in vivo* these mutations strongly reduce rather than promote cell death (Table 1 and Supplementary Table 1). Another CED-3 prodomain mutation, *n2449* (R51H), caused a barely detectable cell death defect (Table 1 and Supplementary Table 1), and the CED-3(R51H) zymogen was indistinguishable from the wild-type CED-3 zymogen in the CED-3 autoactivation assay (Fig. 1a, lanes 13–16, and Supplementary Fig. 1a,c).

Prodomain mutations do not impair CED-3 activation by CED-4

Given the strong cell death defects caused by these three CED-3 prodomain mutations, we examined whether they might impair the activation of the CED-3 zymogen induced by CED-4. Oligomeric CED-4 greatly accelerated autoproteolytic activation of both the wild-type CED-3 zymogen and the CED-3(R51H) zymogen (Fig. 1b, lanes 1–4, 13–16 and Supplementary Fig. 1b,c)^{12,15,20}, leading to the activation of some of the CED-3 zymogens at the 25-min time point (Fig. 1b, lanes 1), when there was no sign of any CED-3 activation in the absence of CED-4 (Fig. 1a, lanes 1). In comparison, oligomeric CED-4 only mildly enhanced autoproteolytic activation of CED-3(L27F), CED-3(L30F) and CED-3(G65R) zymogens (Fig. 1b, lanes 5–12, 17–20, and Supplementary Fig. 1b,c), which already self-activated strongly *in vitro* without CED-4 (Fig. 1a, lanes 5–12, 17–20, and Supplementary Fig. 1a,c). Therefore, in the presence of oligomeric CED-4, all five CED-3 zymogens were activated to a similar level. In contrast, a catalytic-site mutation in CED-3 (G360S) conferred by a strong *lf* mutation *n2433* completely blocked CED-3 zymogen activation with or without CED-4 (Table 1 and Supplementary Fig. 1d). These results indicate that the three CED-3 prodomain mutations (G65R, L27F and L30F) unexpectedly enhance CED-3 autoproteolytic activation and do not affect CED-4-induced CED-3 activation *in vitro*. These findings are inconsistent with the strong cell death defects caused by these mutations and

suggest that they must impair CED-3 activation or activity *in vivo* through a more complex mechanism that was not recapitulated in the *in vitro* assays.

CED-3 displays perinuclear localization in germ cells

To understand how CED-3 acts to kill the cell, we examined the subcellular localization pattern of CED-3 in *C. elegans* using a low-copy integrated transgene expressing a CED-3 translational GFP fusion ($P_{ced-3}ced-3::gfp$), which was generated by biolistic bombardment²¹. This transgene fully rescued the cell death defect of the strong *ced-3(n2433)* mutant (Supplementary Table 2), indicating that this CED-3::GFP fusion is functional and likely localizes to the proper subcellular sites. Interestingly, we observed a perinuclear localization pattern of CED-3::GFP in *C. elegans* germ cells (Fig. 2a), which was not seen when GFP was expressed in germ cells (Supplementary Fig. 2a,b). This perinuclear localization pattern of CED-3::GFP was lost and became diffuse in apoptotic germ cells (Supplementary Fig. 2c), probably due to breakdown of nuclear membrane during apoptosis³. Although CED-3::GFP expressed from a high-copy number transgene was observed in the cytoplasm of some dying cell and its mother in *C. elegans* embryos²², we could not detect clearly visible GFP signal in live somatic cells of *C. elegans* embryos, larvae, or adults carrying this low-copy $P_{ced-3}ced-3::gfp$ transgene. Multiple efforts to generate antibodies to CED-3 failed to produce an antibody that could detect the endogenous CED-3 expression in *C. elegans* either by immunoblotting or by immunohistochemistry (see Online Methods).

C. elegans nuclei inhibit CED-3 autoactivation *in vitro*

Given the perinuclear localization pattern of CED-3, we examined if *C. elegans* nuclei might play a role in regulating CED-3 activation or activity. We purified nuclei from wild-type animals (Supplementary Fig. 2d and see Online Methods)²³ and included them in CED-3 activation or activity assays. In the absence of oligomeric CED-4, the limited self-activation of the wild-type CED-3 zymogen and the CED-3(R51H) zymogen was inhibited by *C. elegans* nuclei (Fig. 3a,b, lanes 1–4, 13–16, and Supplementary Fig. 3a,b,d). Similarly, the originally robust autoactivation of CED-3(L27F), CED-3(L30F) and CED-3(G65R) zymogens was markedly suppressed by purified nuclei (Fig. 3a,b, lanes 5–12, 17–20, and Supplementary Fig. 3a,b,d), resulting in loss of the processed catalytic subunits at approximately 15–17 kD positions^{12,19}. On the other hand, purified nuclei did not inhibit cleavage of CED-9, a known CED-3 substrate²⁴, by the active CED-3 protease (Supplementary Fig. 2e), indicating that nuclei do not affect the activity of active CED-3. These results suggest that *C. elegans* nuclei inhibit autoactivation of both wild-type and mutant CED-3 zymogens *in vitro* and could serve as a negative regulator to inhibit CED-3 autoproteolytic activation *in vivo*.

During apoptosis, CED-4 is released from the CED-4 and CED-9 inhibitory complex tethered on the outer mitochondrial membrane and subsequently oligomerizes to promote CED-3 activation and cell killing^{11,12}. When CED-4 oligomers were included in the CED-3 activation assays with the nuclei, both wild-type CED-3 and CED-3(R51H) zymogens were strongly activated (Fig. 3c, lanes 1–4, 13–16, and Supplementary Fig. 3c,d), indicating that CED-4 oligomers overcome the inhibitory effect of nuclei to induce robust activation of the

CED-3 and CED-3(R51H) zymogens. In contrast, CED-4 oligomers were unable to reverse the inhibition of nuclei to restore strong activation of the CED-3(L27F), CED-3(L30F) and CED-3(G65R) zymogens, and in particular, generation of catalytic subunits at approximately 15–17 kD positions (Fig. 3c, lanes 5–12, 17–20, and Supplementary Fig. 3c,d). These *in vitro* results are consistent with the findings that CED-3 prodomain mutations, L27F, L30F and G65R, but not R51H, cause strong cell death defects in *C. elegans* (Table 1 and Supplementary Table 1).

NPP-14 inhibits cell death in a *ced-3* allele-specific manner

We investigated how CED-3 localizes to the perinuclear region and whether inhibition of the CED-3 zymogen activation by nuclei is mediated by a nuclear membrane protein. Because the CED-3 G65R mutation significantly enhanced CED-3 zymogen autoactivation in the absence of *C. elegans* nuclei (Fig. 3a,b, lanes 17–20), we reasoned that RNA interference (RNAi) knockdown of the nuclear membrane protein that mediates inhibition of CED-3 zymogen autoactivation by nuclei would cause increased cell death in *ced-3(n718 G65R)* animals. Therefore, we performed a candidate-based RNAi screen on *ced-1(e1735); ced-3(n718 G65R)* animals and looked for RNAi treatment that increased the number of persistent cell corpses in *ced-1(e1735); ced-3(n718 G65R)* embryos. Thirty-eight *C. elegans* genes, encoding nuclear membrane proteins or proteins known to associate with the nuclear envelope^{23,25–29}, were screened (Table 2). RNAi of one gene, *npp-14*, which encodes a nuclear pore protein, caused appearance of 1–2 cell corpses in 67% of *ced-1(e1735); ced-3(n718 G65R)* 4-fold stage embryos ($n=15$), while virtually no cell corpse was seen in *ced-1(e1735); ced-3(n718 G65R)* embryos treated with RNAi to other genes (Table 2). We confirmed this result using a loss-of-function *npp-14* mutation (*sm160*), which results in substitution of Glutamine 641 of the NPP-14 protein by an Ocher stop codon (see Online Methods). *npp-14(sm160)* significantly increased the number of persistent cell corpses not only in *ced-1(e1735); ced-3(n718 G65R)* embryos, but also in *ced-1(e1735); ced-3(n1040 L27F)* and *ced-1(e1735); ced-3(n2439 L30F)* embryos (Table 1). For instance, in the *ced-1(e1735); ced-3(n1040 L27F)* double mutant, a mean of 13 cell corpses was seen in 4-fold stage embryos, but in the *npp-14(sm160) ced-1(e1735); ced-3(n1040 L27F)* triple mutant, the number of cell corpses almost doubled (a mean of 23 cell corpses; Table 1), indicating markedly increased cell death. In line with these observations, *npp-14(sm160)* reduced the number of extra cells in the anterior pharynx of *ced-1(e1735); ced-3(n718 G65R)*, *ced-1(e1735); ced-3(n1040 L27F)*, and *ced-1(e1735); ced-3(n2439 L30F)* animals (Supplementary Table 1). On the other hand, loss of *npp-14* did not induce any cell death in *ced-1(e1735); ced-3(n2433 G360S)* embryos, which have the catalytic-dead CED-3 protein (Table 1 and Supplementary Fig. 1d), and did not increase the number of persistent cell corpses in *ced-1(e1735); ced-3(n2449 R51H)* embryos, which have a CED-3 zymogen indistinguishable from the wild-type CED-3 zymogen in autoactivation *in vitro* (Fig. 1a,b). Neither did loss of *npp-14* alter the extra cell numbers in *ced-1(e1735); ced-3(n2433 G360S)* and *ced-1(e1735); ced-3(n2449 R51H)* animals (Supplementary Table 1).

Similarly, inactivation of *npp-14* significantly increased germ cell death in *ced-1(e1735); ced-3(n1040 L27F)* and *ced-1(e1735); ced-3(n2439 L30F)* animals (Supplementary Table 3) and resulted in a greater increase of germ cell death when these animals were subjected to

ultraviolet (UV) irradiation (Supplementary Table 4). As in somatic cells, loss of *npp-14* did not increase germ cell death in *ced-1(e1735); ced-3(n2433 G360S)* or *ced-1(e1735); ced-3(n2449 R51H)* animals with or without UV irradiation (Supplementary Tables 3 and 4). Taken together, these results show that *npp-14* plays an important, allele-specific cell death inhibitory role in three *ced-3* mutants (*n718*, *n1040* and *n2439*) that have CED-3 zymogens with enhanced autoactivation activity.

NPP-14 is critical for CED-3 perinuclear localization

To investigate if *npp-14* affects CED-3 subcellular localization, we introduced the $P_{ced-3}ced-3::gfp$ integrated transgene into the *npp-14(sm160)* mutant and found that CED-3 largely lost its perinuclear localization (Fig. 2b). This result indicates that NPP-14, a nuclear membrane protein, is critical for localization of CED-3 to the perinuclear region. We generated a low-copy number integrated transgene that expressed *npp-14* translational fusion with dsRed from its endogenous promoter ($P_{npp-14}NPP-14::dsRed$) by biolistic bombardment and found that NPP-14::dsRed was colocalized with CED-3::GFP in *C. elegans* germ cells (Fig. 2c). We then tested if NPP-14 directly interacted with CED-3 using GST fusion protein pull-down assays. GST-NPP-14, but not GST alone, bound full-length CED-3 (residues 1–503; Supplementary Fig. 4a) and the prodomain of CED-3 (residues 1–220)(Fig. 4a, lanes 8 and 9), but failed to interact with a fragment of CED-3 containing both catalytic subunits (residues 206–503; Supplementary Fig. 4a). Interestingly, GST-NPP-14 displayed significantly stronger binding to the CED-3 prodomain harboring the L27F, L30F, or G65R mutation than to the wild-type CED-3 prodomain or the mutant CED-3(R51H) prodomain (Fig. 4a, lanes 10–14, Fig. 4b, and Supplementary Fig. 4b). These results together indicate that NPP-14 plays an important role in tethering the CED-3 zymogen to the nuclear membrane through binding to the CED-3 prodomain. The finding that NPP-14 shows stronger binding to three CED-3 zymogens with prodomain mutations that cause strong cell death defects *in vivo* is consistent with the observations that these three mutant zymogens were poorly activated by oligomeric CED-4 in the presence of nuclei *in vitro* (Fig. 3c, lanes 5–12, 17–20, and Supplementary Fig. 3c,d).

NPP-14 regulates CED-3 autoactivation *in vitro*

We last tested whether NPP-14 inhibited CED-3 autoactivation *in vitro* like *C. elegans* nuclei. When recombinant NPP-14 was included in the CED-3 activation assays, the limited self-activation of CED-3 and CED-3(R51H) zymogens was blocked (Fig. 4c,d, lanes 1–4, 13–16, and Supplementary Fig. 5a,b,d) and the strong self-activation of CED-3(L27F), CED-3(L30F) and CED-3(G65R) zymogens was mostly suppressed (Fig. 4c,d, lanes 5–12, 17–20, and Supplementary Fig. 5a,b,d). Consistent with this *in vitro* observation, overexpression of NPP-14 in *C. elegans* inhibited cell death during embryogenesis (Supplementary Fig. 4c). However, when CED-4 oligomers were included in the reactions with NPP-14, the autoproteolytic activation of CED-3 and CED-3(R51H) zymogens was greatly enhanced (Fig. 4e, lanes 1–4, 13–16, and Supplementary Fig. 5c,d). By contrast, the activation of the CED-3(L27F), CED-3(L30F), or CED-3(G65R) zymogen remained largely suppressed (Fig. 4e, lanes 5–12 and lanes 17–20, and Supplementary Fig. 5c,d). Like nuclei, NPP-14 did not inhibit the activity of the active CED-3 protease (Supplementary Fig. 2f). Therefore, NPP-14 mimics nuclei in suppressing CED-4-induced activation of three CED-3

zymogens with prodomain mutations that cause stronger association of CED-3 with NPP-14, but does not affect active CED-3 protease. These results nicely account for the paradoxical observations that CED-3(L27F), CED-3(L30F) and CED-3(G65R) zymogens self-activate strongly *in vitro*, but have a greatly reduced proapoptotic activity *in vivo*.

DISCUSSION

Caspases play pivotal roles in the initiation and execution of apoptosis in diverse organisms^{1-3,30}. The activation and activities of caspases need to be tightly controlled to ensure proper animal development and tissue homeostasis^{1-3,30}. As the prototype of the apoptotic caspases and the key cell-killing protein in *C. elegans*, how the CED-3 caspase is regulated so that it is safely constrained in living cells and specifically activated in apoptotic cells has been a major topic of study. The central unresolved issue is the physical location of the CED-3 zymogen, which governs how it might be activated and how it acts to trigger apoptosis.

In this study, we report that the *C. elegans* CED-3 zymogen is tethered to the nuclear membrane in live germ cells through its interaction with a nuclear pore component NPP-14. This protein interaction and the nuclear membrane association block autoactivation of the CED-3 zymogen *in vitro* and appear to protect cells from inadvertent apoptosis *in vivo*. In cells destined to undergo apoptosis, the activated CED-4 oligomers translocate from mitochondria to the perinuclear region^{11,12}, or accumulate in the perinuclear region¹⁴, where they induce robust activation of the CED-3 zymogen by overcoming the inhibitory effect of NPP-14 and nuclei, leading to the activation of apoptosis. These findings unravel the long-standing questions of how autoactivation of the CED-3 zymogen is curbed in cells that live and why CED-4 needs to translocate to the perinuclear region to activate apoptosis. This is also the first report that a caspase zymogen is targeted to the perinuclear region in living cells and that nuclei play a direct and critical role in regulating appropriate activation of a caspase zymogen.

In mammals, caspase zymogens have not been reported to localize to the perinuclear region or associate with the nuclear membrane. However, several caspases, including caspase-2 and caspase-3, have been found in nuclei or in the nuclear fractions³¹⁻³³, although the importance of such localization to apoptosis and caspase activation is unclear. Moreover, several nuclear pore proteins, such as Nup210, Nup214 and Nup107, have been implicated in suppressing apoptosis in mammalian cells³⁴⁻³⁶. In particular, Nup210 plays an antiapoptotic role to promote skeletal muscle differentiation by suppressing the caspase cascade induced by endoplasmic reticulum (ER) stress accompanying the differentiation process³⁴. Further investigation is needed to examine if association with nuclear membrane proteins represents a conserved mechanism for regulating apoptosis and caspase activation across organisms.

The prodomains or the CARD domains of caspases in mammals play a critical role in caspase activation by recruiting caspase zymogens to specific death-activation complexes, such as the apoptosome or the death receptor signaling complexes, leading to their autocatalytic activation^{1,2,30}. It is thus intriguing that the prodomain of CED-3 appears to be

dispensable for CED-3 activation *in vitro*^{15,16}, yet multiple mutations in the prodomain, including three examined in this study (*n718*, *n1040*, and *n2439*), cause strong cell death defects *in vivo*^{4,17}. In this study, we show that these three prodomain mutations result in stronger association of the CED-3 zymogens with NPP-14, which deters not only CED-3 autocatalytic activation but also CED-3 activation induced by CED-4 oligomers (Figs. 3, 4). This finding provides the mechanistic insight into why these mutations cause strong cell death defects *in vivo*. On the other hand, these three prodomain mutations also cause enhanced CED-3 autoactivation *in vitro*, and consistent with that finding, increased apoptosis *in vivo* in the absence of *npp-14* (Fig. 1). These findings squarely place NPP-14 and *C. elegans* nuclei as the key regulator of CED-3 activation and apoptosis in *C. elegans* and raise the possibility that a similar mechanism may control caspase activation and apoptosis in other organisms.

METHODS

Methods and any associated references are available in the online version of the paper.

ONLINE METHODS

Strains

Strains of *C. elegans* were cultured at 20°C using standard procedures³⁷. Most of the alleles used in this study have been described previously^{17,18}, except the *npp-14(sm160)* allele.

Isolation of the *npp-14(sm160)* mutation

Ethyl methane sulfonate (EMS) mutagenesis was performed on *ced-9(n2812); ced-3(n717)* animals carrying an extrachromosomal transgene array (*smEx588*) containing $P_{hsp}CED-4::GFP$ and pRF4, a transgenic marker causing the Rol phenotype. Upon heat-shock treatment, CED-4::GFP localizes to the nuclear membrane due to loss of *ced-9*. *sm160* was isolated as a recessive mutation that prevents CED-4::GFP localization to the nuclear membrane and was found to cause a C to T transition in the *npp-14* gene that generates a stop codon at amino acid 641 (Q641Ocher).

Quantification of cell corpses

Somatic cell corpses in the head region of 3-fold transgenic embryos or 4-fold stage embryos were scored using Nomarski optics, as previously described³⁸. The number of germ cell corpses in the pachytene region of one gonad arm of hermaphrodite animals was scored using Nomarski optics. 15 animals were scored at 24 hours or 48 hours post L4 to the adult molt for each strain.

Quantification of extra cells

The number of extra cells in the anterior pharynx of L4 larvae was scored using Nomarski optics, as previously described³⁸. 20 animals were scored for each strain.

Quantification of germ cell death induced by UV irradiation

To assess the effect of UV irradiation on germ cell death, hermaphrodite animals were allowed to develop to the young adult stage (24 hours after L4 to the adult molt) at 20°C and treated with 100 J/m² UV on non-seeded NGM plates using a Stratalinker (Stratagene, Inc.). Immediately after UV irradiation, animals were transferred to freshly seeded NGM plates and germ cell corpses were scored 6 hours or 24 hours later as indicated.

Generation of transgenic animals

$P_{hsp}npp-14$ (25 µg/ml each) and $P_{sur-5}gfp$ (25 µg/ml), which was used as a transgenic marker, were injected into *ced-1(e1735)* animals to generate transgenic lines. To express GFP in *C. elegans* germ line under the control of the heat-shock promoters, a mixture of the following DNA constructs were injected into the N2 animals to create complex transgenic arrays that facilitate gene expression in the germ line: the $P_{hsp}gfp$ expression constructs linearized with *Hind III* (1 µg/ml each), the pRF4 construct linearized with *EcoR I* (1 µg/ml) and the $P_{sur-5}mcherry$ construct (1 µg/ml), which serve as transgenic markers, and wild-type *C. elegans* genomic DNA digested with *Sca I* (60 µg/ml). F3, F4 and F5 generations of Roller transgenic animals were examined and imaged for the expression of GFP in the germ line after the heat-shock treatment.

Heat-Shock Treatment

Roller transgenic animals were placed at 33°C for 60 minutes and let recover at 20°C for 3 hours before imaging.

Molecular Biology

To generate the $P_{ced-3}ced-3::gfp$ translational fusion construct for biolistic bombardment, we first replaced the stop codon of the *ced-3* coding region in the pJ40 vector with an *Nhe I* site through site-directed mutagenesis⁴, which contains 2387 bp of the *ced-3* promoter and 2275 bp of 3' untranslated region. A GFP coding region was then inserted into the modified vector through the newly created *Nhe I* site. A 10 kb *Bam HI/Apa I* fragment containing the *ced-3::gfp* fusion was excised from the vector and inserted into a vector used for biolistic bombardment, which also contains the *C. elegans unc-119* gene. To generate the $P_{npp-14}npp-14::dsRed$ fusion construct for biolistic bombardment, a 7173 bp PCR fragment containing the *npp-14* coding region including 2603 bp of the *npp-14* promoter was inserted into a modified pPD95.77 vector, in which the GFP coding region was replaced by the dsRed coding region. A 8.7 kb *Pst I/Spe I* fragment containing the *npp-14::dsRed* fusion was excised from the resulting construct and inserted into the same bombardment vector described above.

Protein expression and purification

CED-4 oligomers were expressed and purified as previously described¹². A partial cDNA clone (*yk1144d07*) containing *npp-14* and a cDNA fragment containing the part of *npp-14* that is missing in the *yk1144d07* clone, which was generated by reverse transcription polymerase chain reaction (RT-PCR), were used to assemble the full-length *npp-14* cDNA clone. The full-length *npp-14* cDNA fragment was subcloned into the pET-15b vector via its

Nde I and *Xho I* sites and the resulting construct was used to express NPP-14 in the bacterial strain BL21(DE3) as an N-terminal His₆-tagged protein. After 3 hour induction at 22°C, cells were collected and lysed. His₆-NPP-14 was purified from the soluble fraction using a Ni²⁺-NTA column (GE Healthcare) and further dialyzed by a buffer containing 25 mM Tris (pH8.0), 150 mM NaCl, 1 mM DTT, and 10% (v/v) Glycerol. The *ced-3* cDNA fragments encoding amino acids 1–220 (wild-type or with prodomain mutations) with a C-terminal His₆ tag were subcloned into the pET-3a vector via its *Nde I* and *BamHI* sites to generate the CED-3(1–220)-His₆ expression constructs (wild-type or mutant). CED-3(1–220)-His₆ proteins (wild-type or mutant) were expressed in the bacterial strain BL21(DE3), and after 4 hour induction at 22°C, cells were collected and lysed. CED-3(1–220)-His₆ proteins (wild-type or mutant) were purified from the soluble fraction using a Ni²⁺-NTA column and were eluted from the column in a buffer containing 100 mM Tris (pH8.0), 250 mM NaCl, 0.5mM Sucrose, 0.04% NP-40, 1 mM DTT, 250mM Imidazole and 10% (v/v) Glycerol. The concentrations of purified proteins were determined by spectroscopic measurement at 280 nm.

CED-3 zymogen activation assays *in vitro*

The CED-3 expression vector, pTRI-CED-3¹², was used to generate other pTRI-CED-3 vectors carrying the prodomain mutations, L27F, L30F, R51H, G65R, or G360S, using a QuickChange Site-Directed Mutagenesis kit (Stratagene). All constructs were confirmed by DNA sequencing.

CED-3 zymogens (wild-type or mutant) were synthesized and labeled with ³⁵S-Methionine in the TNT Transcription/Translation coupled system (Promega) at 30°C for 20 min. CED-4 oligomers, *C. elegans* nuclei, purified NPP-14, or buffer controls were then added to the reactions. At different time points, an aliquot was taken out and SDS sample loading buffer was added to stop the reaction. The samples were resolved by 15% SDS polyacrylamide gels (PAGE), which were fixed, dried and subjected to autoradiography. CED-4 buffer contains 25 mM Tris (pH8.0), 200 mM NaCl, and 10% (v/v) Glycerol. The nuclei buffer contains 20 mM HEPES (pH 7.6), 20 mM KCl, 3 mM MgCl₂, 2 mM EGTA, 0.5 M sucrose, 10% (v/v) Glycerol, and 1 mM DTT. The NPP-14 buffer contains 25 mM Tris (pH8.0), 150 mM NaCl, 1 mM DTT, and 10% (v/v) Glycerol.

CED-3 activity assays *in vitro*

CED-9 was synthesized and labeled with ³⁵S-Methionine in the Transcription & Translation coupled system (Promega) for 1 hour at 30°C as described above. 10 ng of purified, active CED-3 were incubated with ³⁵S-Methionine-labeled CED-9 in the presence of *C. elegans* nuclei, recombinant NPP-14, or the caspase inhibitor (iodoacetic acid) for 1 hour at 30°C. After that, SDS loading buffer was added to stop the reaction. The samples were resolved by 15% SDS-PAGE and subjected to autoradiography. CED-3 buffer contains 100 mM Tris (pH8.0), 250 mM NaCl, 0.5 mM sucrose, 7.5mM beta-mercaptoethanol, 0.04% (v/v) NP-40, and 10% (v/v) Glycerol.

Quantifying the intensity of CED-3 bands from gel images

SDS-PAGE gels were dried and then subjected to autoradiography to obtain corresponding gel images, which were converted by scanner to images that could be opened in Image J software (<https://imagej.nih.gov/ij/>). The intensity of CED-3 bands of interest was measured and recorded for further quantification.

Isolation of *C. elegans* nuclei

Isolation of *C. elegans* nuclei was carried out using a previously described protocol with minor modifications²³. Wild-type *C. elegans* animals carrying an integrated transgene *ccIs4810*³⁹, which expresses a lamin GFP fusion and allows quantification of isolated nuclei, were used to isolate nuclei. Adult *ccIs4810* animals were harvested, washed with M9 buffer, resuspended in an equal volume of cold PBS, snap-freeze in liquid nitrogen, and stored at -80°C overnight. The animals were thawed and immediately transferred to a pre-chilled Wheaton stainless-steel tissue grinder and homogenized in an equal volume of cold 2X nuclei preparation buffer [20 mM HEPES (pH 7.6), 20 mM KCl, 3 mM MgCl_2 , 2 mM EGTA, 0.5 M sucrose, 1 mM DTT, and protease inhibitors]. Debris was spun down at 1000 rpm for 1 min to remove unbroken worm bodies and supernatants containing nuclei were collected. Homogenization and collection of nuclei were repeated twice. Supernatants from the first and the second collections were pooled and centrifuged at 3000 rpm for 10 min to obtain the nuclei in the pellets. Nuclei were then washed twice using the nuclei TNT assay buffer [20 mM HEPES (pH 7.6), 20 mM KCl, 3 mM MgCl_2 , 2 mM EGTA, 0.5 M sucrose, 10% (v/v) Glycerol, and 1 mM DTT] and resuspended in 4 volumes of nuclei TNT assay buffer.

Imaging CED-3 and NPP-14 localization in germ cells

The subcellular localization of CED-3::GFP as well as NPP-14::dsRed was examined in dissected gonads from $P_{ced-3}ced-3::gfp, npp-14(sm160); P_{ced-3}ced-3::gfp$, and $P_{ced-3}ced-3::gfp; P_{npp-14}npp-14::dsRed$ adult hermaphrodites. Gonads were gently dissected out from 24-hour old adult hermaphrodites by cutting them at the head region on a slide while immersed in a gonad dissection buffer [60 mM NaCl, 32 mM KCl, 3 mM Na_2HPO_4 , 2 mM MgCl_2 , 20 mM HEPES, 10 mM Glucose, 33% (w/v) fetal calf serum, and 2 mM CaCl_2]⁴⁰. 5 μM of Hoechst33342 were then added to the buffer containing the dissected gonads. The dissected gonads were mounted on the slide and visualized using a Nomarski microscope equipped with epifluorescence.

RNAi screen

The bacteria feeding protocol was used in all RNAi experiments⁴¹. Approximately 30 L4-stage larvae were transferred to RNAi plates. Progeny of RNAi-treated animals were scored for persistent cell corpses at the 4-fold embryonic stage. To determine the survival rate in each RNAi experiment, 30 L3-L4 larvae were transferred from a plate seeded with OP50 bacteria to an RNAi plate. Two days later, 20 adult animals were transferred from the original RNAi plate to a new RNAi plate. The adult animals were allowed to lay eggs for 1 hour before they were removed and the number of eggs laid on the plate was recorded. Three days later, the number of eggs that hatched out to become larvae was scored and used to

determine the survival rate. RNAi knockdown of multiple genes resulted in different degrees of embryonic lethality, but allowed scoring of cell corpses in some surviving embryos.

GST fusion protein pull-down assays

GST was expressed from the expression vector, pGEX-4T-1. The full-length *npp-14* cDNA was subcloned into the pPGH vector (a derivative of pGEX-4T-2) via its *Nde I* and *Hind III* sites to generate the GST-NPP-14 expression construct. cDNA fragments encoding full-length CED-3 or residues 206–503 of CED-3 with an A449V mutation that inactivates the activity of the CED-3 protease¹⁹ and a C-terminal FLAG tag were subcloned into the pET-3a vector via its *Nde I* and *BamH I* sites. The A449V mutation was generated using a two-step PCR procedure and allows synthesis of CED-3 in bacteria without autoproteolytic cleavage. Bacterial lysate containing GST or GST-NPP-14 was incubated with the glutathione Sepharose beads (GE Healthcare) in the reaction buffer containing 50 mM Tris (pH8.0), 100 mM NaCl, 0.1% (v/v) NP-40, 10% (v/v) Glycerol, and 2 mM DTT at 4°C for 1 hour before washed five times with the binding buffer [50 mM Tris (pH8.0), 300 mM NaCl, 0.2% (v/v) NP-40, 1 mM DTT, and 5 mg/ml BSA]. The glutathione Sepharose beads with immobilized GST or GST-NPP-14 were then incubated with 4 nM of purified wild-type CED-3(1–220)-His₆ or CED-3(1–220)-His₆ carrying the indicated mutation or bacterial lysate containing 3.5 nM CED-3(A449V)-FLAG or CED-3(206–503, A449V)-FLAG at 4°C for 1 hour in 1 ml binding buffer. Subsequently, the Sepharose beads were washed five times with the washing buffer [50 mM Tris (pH8.0), 300 mM NaCl, 0.2% (v/v) NP-40, and 1 mM DTT] and the bound proteins were resolved by 15% SDS-PAGE, transferred to a PVDF membrane, and detected by immunoblotting.

Immunoblotting

The CED-3(1–220)-His₆ proteins (wild-type or mutant) bound to the Sepharose beads in the pull-down assays were resolved by 15% SDS-PAGE and transferred to the PVDF membrane (Millipore). The membrane was first blocked with 5% nonfat dry milk (Bio-Rad) in PBS-T (PBS with 0.1% Tween 20) for 1 hour and then incubated with a mouse anti-His₆ antibody (Proteintech, Cat. no. 66005-I-Ig) in 1:6000 dilution for 2 hour at room temperature. The membrane was washed three times with PBS-T for 5 min each. HRP-conjugated goat anti-mouse IgG antibody (Bio-Rad, Cat. no. 170–5047) was then added to the membrane in 1:5000 dilution for 1 hour at room temperature. The membrane was then washed three more times with PBS-T and the proteins were detected with enhanced chemiluminescent substrate (Pierce). For anti-FLAG immunoblotting, a mouse anti-FLAG antibody (CWbiotech, Cat. no. CW0287A) was used in 1:2000 dilution and HRP-conjugated goat anti-mouse IgG (Bio-Rad cat. no. 170–5047) was used in 1:5000 dilution. For immunoblotting analyses to examine purified nuclei, adult *ccIs4810* animals were harvested from NGM plates with M9, centrifuged at 500 g to remove bacteria, and sonicated in PBS buffer to generate the worm lysate. 2× SDS loading buffer was added to purified *ccIs4810* nuclei and *ccIs4810* lysate. The samples were then resolved with 12% SDS-PAGE, transferred to a PVDF membrane, and detected using different antibodies. For the GFP immunoblot (a nuclear membrane marker), a rabbit anti-GFP antibody was used in 1:1500 dilution (Proteintech, Cat. no. 50430-2-AP) and a HRP-conjugated goat anti-rabbit IgG (CWbiotech, Cat. no. CW0103) was used in 1:5,000 dilution. For the α -tubulin immunoblot (a cytoskeletal marker), a mouse

anti- α -tubulin antibody (Developmental Studies Hybridoma Bank, Cat. no. AA4.3) was used in 1:5,000 dilution and a HRP-conjugated goat anti-mouse IgG (Bio-Rad, Cat. no. 170-5047) was used in 1:5,000 dilution. For the DLG-1 immunoblot (a plasma membrane marker)⁴², a mouse anti-DLG-1 antibody (Developmental Studies Hybridoma Bank, Cat. no. DLG1) was used in 1:1000 dilution and a HRP-conjugated goat anti-mouse IgG (Bio-Rad cat. no. 170-5047) was used in 1:5,000 dilution. For the HSP-60 immunoblot (a mitochondrial marker)⁴², a mouse anti-HSP-60 antibody (Developmental Studies Hybridoma Bank, Cat. no. HSP60) was used in 1:200 dilution and a HRP-conjugated goat anti-mouse IgG (Bio-Rad cat. no. 170-5047) was used in 1:5,000 dilution. For the HDEL immunoblot (an ER marker), a mouse anti-HDEL antibody (Santa Cruz Biotechnology, cat. no. sc-53472, validated by 1DegreeBio) was used in 1:100 dilution and a HRP-conjugated goat anti-mouse IgG (Bio-Rad cat. no. 170-5047) was used in 1:5,000 dilution.

Generation of CED-3 antibodies

Purified CED-3(206-503; A449V)-His₆ was used to immunize four rabbits, two rats, and multiple mice to generate either polyclonal or monoclonal antibodies against CED-3. None of the serum, even after affinity purification using CED-3, and none of the monoclonal antibodies from eight different hybridoma cell lines, could detect the CED-3 protein in *C. elegans* either by immunoblotting or by immunohistochemistry.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments


We thank C.L. Sun for generating the $P_{npp-1}\Delta NPP-14::dsRed$ integrated transgene, X.C. Wang for isolating the *sm160* allele, J. Friedman for identifying the *sm160* mutation in *npp-14*, and Y.G. Shi (Tsinghua University) and M. Han (University of Colorado) for providing vectors. This work was supported by National Basic Research Program of China (973 program 2013CB945600), National Institutes of Health (NIH) grants T32GM007135 and F30NS070596 (B.H.), and NIH grants R01 GM59083, R01 GM88241, and R35 GM118188 (D.X.)

References

1. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. *Nat Rev Mol Cell Biol.* 2004; 5:897–907. [PubMed: 15520809]
2. Salvesen GS, Riedl SJ. Caspase mechanisms. *Adv Exp Med Biol.* 2008; 615:13–23. [PubMed: 18437889]
3. Crawford ED, Wells JA. Caspase substrates and cellular remodeling. *Annu Rev Biochem.* 2011; 80:1055–1087. [PubMed: 21456965]
4. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The *C. elegans* cell death gene *ced-3* encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. *Cell.* 1993; 75:641–652. [PubMed: 8242740]
5. Li J, Yuan J. Caspases in apoptosis and beyond. *Oncogene.* 2008; 27:6194–6206. [PubMed: 18931687]
6. Yuan J, Horvitz HR. The *Caenorhabditis elegans* cell death gene *ced-4* encodes a novel protein and is expressed during the period of extensive programmed cell death. *Development.* 1992; 116:309–320. [PubMed: 1286611]

7. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to *C. elegans* CED-4, participates in cytochrome c-dependent activation of caspase-3. *Cell*. 1997; 90:405–413. [PubMed: 9267021]
8. Spector MS, Desnoyers S, Hoepfner DJ, Hengartner MO. Interaction between the *C. elegans* cell-death regulators CED-9 and CED-4. *Nature*. 1997; 385:653–656. [PubMed: 9024666]
9. Chinnaiyan AM, O'Rourke K, Lane BR, Dixit VM. Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. *Science*. 1997; 275:1122–1126. [PubMed: 9027312]
10. Wu D, Wallen HD, Nunez G. Interaction and regulation of subcellular localization of CED-4 by CED-9. *Science*. 1997; 275:1126–1129. [PubMed: 9027313]
11. Chen F, et al. Translocation of *C. elegans* CED-4 to nuclear membranes during programmed cell death. *Science*. 2000; 287:1485–1489. [PubMed: 10688797]
12. Yan N, et al. Structure of the CED-4-CED-9 complex provides insights into programmed cell death in *Caenorhabditis elegans*. *Nature*. 2005; 437:831–837. [PubMed: 16208361]
13. Conradt B, Wu YC, Xue D. Programmed Cell Death During *Caenorhabditis elegans* Development. *Genetics*. 2016; 203:1533–1562. [PubMed: 27516615]
14. Pourkarimi E, Greiss S, Gartner A. Evidence that CED-9/Bcl2 and CED-4/Apaf-1 localization is not consistent with the current model for *C. elegans* apoptosis induction. *Cell Death Differ*. 2012; 19:406–415. [PubMed: 21886181]
15. Qi S, et al. Crystal structure of the *Caenorhabditis elegans* apoptosome reveals an octameric assembly of CED-4. *Cell*. 2010; 141:446–457. [PubMed: 20434985]
16. Huang W, et al. Mechanistic insights into CED-4-mediated activation of CED-3. *Genes Dev*. 2013; 27:2039–2048. [PubMed: 24065769]
17. Shaham S, Reddien PW, Davies B, Horvitz HR. Mutational analysis of the *Caenorhabditis elegans* cell-death gene *ced-3*. *Genetics*. 1999; 153:1655–1671. [PubMed: 10581274]
18. Ellis RE, Jacobson DM, Horvitz HR. Genes required for the engulfment of cell corpses during programmed cell death in *Caenorhabditis elegans*. *Genetics*. 1991; 129:79–94. [PubMed: 1936965]
19. Xue D, Shaham S, Horvitz HR. The *Caenorhabditis elegans* cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. *Genes Dev*. 1996; 10:1073–1083. [PubMed: 8654923]
20. Geng X, et al. Inhibition of CED-3 zymogen activation and apoptosis in *Caenorhabditis elegans* by caspase homolog CSP-3. *Nat Struct Mol Biol*. 2008; 15:1094–1101. [PubMed: 18776901]
21. Praitis V, Casey E, Collar D, Austin J. Creation of low-copy integrated transgenic lines in *Caenorhabditis elegans*. *Genetics*. 2001; 157:1217–1226. [PubMed: 11238406]
22. Chakraborty S, Lambie EJ, Bindu S, Mikeladze-Dvali T, Conradt B. Engulfment pathways promote programmed cell death by enhancing the unequal segregation of apoptotic potential. *Nat Commun*. 2015; 6:10126. [PubMed: 26657541]
23. D'Angelo MA, Raices M, Panowski SH, Hetzer MW. Age-dependent deterioration of nuclear pore complexes causes a loss of nuclear integrity in postmitotic cells. *Cell*. 2009; 136:284–295. [PubMed: 19167330]
24. Xue D, Horvitz HR. *Caenorhabditis elegans* CED-9 protein is a bifunctional cell-death inhibitor. *Nature*. 1997; 390:305–308. [PubMed: 9384385]
25. Hoelz A, Debler EW, Blobel G. The structure of the nuclear pore complex. *Annu Rev Biochem*. 2011; 80:613–643. [PubMed: 21495847]
26. Adam SA. The nuclear transport machinery in *Caenorhabditis elegans*: A central role in morphogenesis. *Semin Cell Dev Biol*. 2009; 20:576–581. [PubMed: 19577735]
27. Minn IL, Rolls MM, Hanna-Rose W, Malone CJ. SUN-1 and ZYG-12, mediators of centrosome-nucleus attachment, are a functional SUN/KASH pair in *Caenorhabditis elegans*. *Mol Biol Cell*. 2009; 20:4586–4595. [PubMed: 19759181]
28. Gorjanacz M, Jaedicke A, Mattaj IW. What can *Caenorhabditis elegans* tell us about the nuclear envelope? *FEBS Lett*. 2007; 581:2794–2801. [PubMed: 17418822]

29. Malone CJ, Fixsen WD, Horvitz HR, Han M. UNC-84 localizes to the nuclear envelope and is required for nuclear migration and anchoring during *C. elegans* development. *Development*. 1999; 126:3171–3181. [PubMed: 10375507]
30. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. *Annu Rev Cell Dev Biol*. 1999; 15:269–290. [PubMed: 10611963]
31. Colussi PA, Harvey NL, Kumar S. Prodomain-dependent nuclear localization of the caspase-2 (Nedd2) precursor. A novel function for a caspase prodomain. *J Biol Chem*. 1998; 273:24535–24542. [PubMed: 9733748]
32. van Loo G, et al. Caspases are not localized in mitochondria during life or death. *Cell Death Differ*. 2002; 9:1207–1211. [PubMed: 12404119]
33. Kumar S. Caspase function in programmed cell death. *Cell Death Differ*. 2007; 14:32–43. [PubMed: 17082813]
34. Gomez-Cavazos JS, Hetzer MW. The nucleoporin gp210/Nup210 controls muscle differentiation by regulating nuclear envelope/ER homeostasis. *J Cell Biol*. 2015; 208:671–681. [PubMed: 25778917]
35. Bhattacharjya S, et al. Inhibition of nucleoporin member Nup214 expression by miR-133b perturbs mitotic timing and leads to cell death. *Mol Cancer*. 2015; 14:42. [PubMed: 25743594]
36. Banerjee HN, Gibbs J, Jordan T, Blackshear M. Depletion of a single nucleoporin, Nup107, induces apoptosis in eukaryotic cells. *Mol Cell Biochem*. 2010; 343:21–25. [PubMed: 20490895]
37. Brenner S. The genetics of *Caenorhabditis elegans*. *Genetics*. 1974; 77:71–94. [PubMed: 4366476]
38. Stanfield GM, Horvitz HR. The *ced-8* gene controls the timing of programmed cell deaths in *C. elegans*. *Mol Cell*. 2000; 5:423–433. [PubMed: 10882128]
39. Liu J, et al. Essential roles for *Caenorhabditis elegans* lamin gene in nuclear organization, cell cycle progression, and spatial organization of nuclear pore complexes. *Mol Biol Cell*. 2000; 11:3937–3947. [PubMed: 11071918]
40. Wang X, et al. *C. elegans* mitochondrial factor WAH-1 promotes phosphatidylserine externalization in apoptotic cells through phospholipid scramblase SCRM-1. *Nat Cell Biol*. 2007; 9:541–549. [PubMed: 17401362]
41. Timmons L, Court DL, Fire A. Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in *Caenorhabditis elegans*. *Gene*. 2001; 263:103–112. [PubMed: 11223248]
42. Hadwiger G, Dour S, Arur S, Fox P, Nonet ML. A monoclonal antibody toolkit for *C. elegans*. *PLoS One*. 2010; 5:e10161. [PubMed: 20405020]

**Figure 1.**

Three unique CED-3 prodomain mutations affect CED-3 autoactivation *in vitro*. **(a,b)** Autoradiographs of SDS-PAGE showing time-course of CED-3 activation *in vitro*. The indicated CED-3 zymogens (wild-type or mutant, synthesized and labeled with ^{35}S -Methionine *in vitro*, see Online Methods) were incubated for different times before stopping the reaction. In **a**, samples were incubated with buffer; in **b**, samples were incubated with oligomeric CED-4 (100 nM final concentration). The cartoon below shows deduced CED-3 processed products derived from cleavage at D221 and D374¹⁹. The deduced CED-3 processed bands on gels are indicated with corresponding color arrows. The 15 kDa and 17 kDa bands could not be resolved clearly on the gels. The original gel images are shown in Supplementary Data Set 1.




Figure 2. CED-3 localizes to the perinuclear region in *C. elegans* germ cells. (a,b) Images of GFP, Hoechst33342, and GFP/Hoechst33342 merged from the exposed gonads of hermaphrodite adult animals with the indicated genotypes are shown. (c) Images of GFP, dsRed, and GFP/dsRed merged from the exposed gonad of an N2 hermaphrodite adult carrying the integrated $P_{ced-3}ced-3::gfp$ and $P_{npp-14}npp-14::dsRed$ transgenes. Scale bars indicate 10 μ m.




Figure 3.

C. elegans nuclei inhibit CED-3 zymogen autoactivation *in vitro*. **(a-c)** Autoradiographs of SDS-PAGE showing time-course of CED-3 activation *in vitro*, performed as described in Fig. 1. CED-3 zymogens were incubated with buffer **(a)**, *C. elegans* nuclei **(b)**, or oligomeric CED-4 (4 nM final concentration) and *C. elegans* nuclei **(c)**. The deduced CED-3 processed bands on gels are indicated as described in Fig. 1. The original gel images are shown in Supplementary Data Set 1.




Figure 4. NPP-14 interacts with the prodomain of CED-3 to inhibit CED-3 zymogen activation. **(a)** Results of pull-down experiments between GST or GST-NPP-14 and 4 nM of purified CED-3(1-220)-His₆ (wild-type or mutant, see Online Methods). Lanes 1 and 2 show Coomassie Blue staining. Lanes 3–14 show immunoblotting using an antibody to the His₆ tag. **(b)** The relative binding affinity of NPP-14 to different CED-3 prodomains. The average intensity of the CED-3(1-220)-His₆ bands shown in Fig. 4a in 5 independent pull-down experiments was determined by Image J (see Online Methods). In each experiment, the

binding between wild-type CED-3(1-220)-His₆ and NPP-14 was set as 100. Error bars are s.d. ** $P < 0.01$. * $P < 0.05$ (two-sided t -tests). (c–e) Autoradiographs of SDS-PAGE showing time-course of CED-3 activation *in vitro*, performed as described in Fig. 1. CED-3 zymogens were incubated with buffer (c), NPP-14 (125 nM final concentration, d), or oligomeric CED-4 (80 nM final concentration) and NPP-14 (125 nM final concentration)(e). The original gel images are shown in Supplementary Data Set 1.

Table 1

Loss of *npp-14* causes increased cell death in several *ced-3* mutants carrying specific prodomain mutations.

| Genotype | No. of cell corpses | Range of cell corpses |
|---|---------------------|-----------------------|
| <i>ced-1(e1735)</i> | 31.3±2.2 | 27 – 34 |
| <i>npp-14(sm160) ced-1(e1735)</i> | 29.4±2.1 * | 26 – 34 |
| <i>ced-1(e1735); ced-3(n2433 G360S)</i> | 0±0 | 0 – 0 |
| <i>npp-14(sm160) ced-1(e1735); ced-3(n2433 G360S)</i> | 0±0 | 0 – 0 |
| <i>ced-1(e1735); ced-3(n718 G65R)</i> | 0.1±0.4 | 0 – 1 |
| <i>npp-14(sm160) ced-1(e1735); ced-3(n718 G65R)</i> | 2.9±0.8 ** | 2 – 4 |
| <i>ced-1(e1735); ced-3(n1040 L27F)</i> | 13.2±1.6 | 11 – 16 |
| <i>npp-14(sm160) ced-1(e1735); ced-3(n1040 L27F)</i> | 22.9±1.6 ** | 21 – 26 |
| <i>ced-1(e1735); ced-3(n2439 L30F)</i> | 7.2±0.9 | 6 – 9 |
| <i>npp-14(sm160) ced-1(e1735); ced-3(n2439 L30F)</i> | 11.3±1.8 ** | 9 – 15 |
| <i>ced-1(e1735); ced-3(n2449 R51H)</i> | 29.2±2.6 | 26 – 35 |
| <i>npp-14(sm160) ced-1(e1735); ced-3(n2449 R51H)</i> | 28.0±1.5 | 26 – 31 |

Cell corpses were scored in 4-fold stage embryos. Data shown are mean ± s.d. ($n = 15$ embryos). The significance of difference in cell corpse numbers between two strains with and without *npp-14(sm160)* was determined by two-sided *t*-tests.

** $P < 0.0001$.

* $P < 0.05$.

Others have $P > 0.05$.

Table 2

An RNAi screen to identify the nuclear membrane protein involved in inhibition of CED-3 autoactivation

| Gene | Protein | RNAi phenotype | Cell corpse number | Survival rate |
|---------------|--------------------------------|----------------|--------------------|---------------|
| <i>npp-1</i> | Nuclear pore complex protein | – | 0.06 | 37% |
| <i>npp-2</i> | Nuclear pore complex protein | – | 0 | 4% |
| <i>npp-3</i> | Nuclear pore complex protein | lethal | ND | 0% |
| <i>npp-4</i> | Nuclear pore complex protein | – | 0.06 | 6% |
| <i>npp-5</i> | Nuclear pore complex protein | – | 0.06 | 23% |
| <i>npp-6</i> | Nuclear pore complex protein | – | 0 | 4% |
| <i>npp-7</i> | Nuclear pore complex protein | lethal | ND | 0% |
| <i>npp-8</i> | Nuclear pore complex protein | lethal | ND | 0% |
| <i>npp-9</i> | Nuclear pore complex protein | lethal | ND | 0% |
| <i>npp-10</i> | Nuclear pore complex protein | lethal | ND | 0% |
| <i>npp-12</i> | Nuclear pore complex protein | – | 0.11 | 65% |
| <i>npp-14</i> | Nuclear pore complex protein | + | 0.73 | 37% |
| <i>npp-15</i> | Nuclear pore complex protein | – | 0.13 | 13% |
| <i>npp-16</i> | Nuclear pore complex protein | – | 0.07 | 36% |
| <i>npp-17</i> | Nuclear pore complex protein | – | 0 | 51% |
| <i>npp-18</i> | Nuclear pore complex protein | – | 0.07 | 78% |
| <i>npp-19</i> | Nuclear pore complex protein | lethal | ND | 0% |
| <i>npp-20</i> | Nuclear pore complex protein | lethal | ND | 0% |
| <i>npp-21</i> | Nuclear pore complex protein | lethal | ND | 0% |
| <i>npp-23</i> | Nuclear pore complex protein | – | 0.10 | 78% |
| <i>unc-84</i> | Inner nuclear membrane protein | – | 0.06 | 71% |
| <i>sun-1</i> | Inner nuclear membrane protein | – | 0 | 10% |
| <i>unc-83</i> | Outer nuclear membrane protein | – | 0 | 70% |
| <i>anc-1</i> | Outer nuclear membrane protein | – | 0.13 | 74% |
| <i>zyg-12</i> | Outer nuclear membrane protein | – | 0.13 | 2% |
| <i>lem-2</i> | Lamin-binding protein | – | 0.12 | 73% |
| <i>lem-3</i> | Lamin-binding protein | – | 0 | 72% |
| <i>emr-1</i> | Lamin-binding protein | – | 0.06 | 78% |
| <i>ran-1</i> | Nuclear import/export | lethal | ND | 0% |
| <i>ran-2</i> | Nuclear import/export | – | 0 | 67% |
| <i>ran-3</i> | Nuclear import/export | – | 0.07 | 74% |
| <i>ran-4</i> | Nuclear import/export | – | 0 | 11% |
| <i>ran-5</i> | Nuclear import/export | – | 0.07 | 61% |
| <i>ima-1</i> | Importin alpha family | – | 0.18 | 67% |
| <i>ima-2</i> | Importin alpha family | – | 0 | 13% |
| <i>ima-3</i> | Importin alpha family | – | 0.07 | 27% |
| <i>imb-2</i> | Importin beta family | – | 0.07 | 48% |
| <i>imb-6</i> | Importin beta family | – | 0.13 | 67% |

At least 12 *ced-1(e1735); ced-3(n718G65R)* embryos were scored in each RNAi experiment. Animals treated with control RNAi had a mean of 0.07 cell corpses ($n=15$). “–” indicates RNAi treatment with no detectable effect. “+” indicates RNAi treatment that substantially increased the

number of persistent cell corpses. RNAi knockdown of several genes resulted in the “lethal” phenotype with no progeny, which prevented cell corpse counting (not determined or ND).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript